192 related articles for article (PubMed ID: 18201586)
21. Intravenous versus oral iron therapy for postpartum anaemia.
Bhandal N; Russell R
BJOG; 2006 Nov; 113(11):1248-52. PubMed ID: 17004982
[TBL] [Abstract][Full Text] [Related]
22. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
23. Use of iron sucrose in dialysis patients sensitive to iron dextran.
Haddad A; Abbadi R; Marji A
Saudi J Kidney Dis Transpl; 2009 Mar; 20(2):208-11. PubMed ID: 19237805
[TBL] [Abstract][Full Text] [Related]
24. Effect of intravenous ascorbic acid medication on serum levels of soluble transferrin receptor in hemodialysis patients.
Tarng DC; Hung SC; Huang TP
J Am Soc Nephrol; 2004 Sep; 15(9):2486-93. PubMed ID: 15339999
[TBL] [Abstract][Full Text] [Related]
25. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
Sav T; Tokgoz B; Sipahioglu MH; Deveci M; Sari I; Oymak O; Utas C
Ren Fail; 2007; 29(4):423-6. PubMed ID: 17497463
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
[TBL] [Abstract][Full Text] [Related]
27. Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron.
Prakash M; Upadhya S; Prabhu R
Clin Chim Acta; 2005 Oct; 360(1-2):194-8. PubMed ID: 15979061
[TBL] [Abstract][Full Text] [Related]
28. Effects of intravenous iron on mononuclear cells during the haemodialysis session.
Martin-Malo A; Merino A; Carracedo J; Alvarez-Lara MA; Ojeda R; Soriano S; Crespo R; Ramirez R; Aljama P
Nephrol Dial Transplant; 2012 Jun; 27(6):2465-71. PubMed ID: 22207322
[TBL] [Abstract][Full Text] [Related]
29. The erythromycin breath test predicts the clearance of midazolam.
Lown KS; Thummel KE; Benedict PE; Shen DD; Turgeon DK; Berent S; Watkins PB
Clin Pharmacol Ther; 1995 Jan; 57(1):16-24. PubMed ID: 7828377
[TBL] [Abstract][Full Text] [Related]
30. A 12-week randomised study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia.
Westad S; Backe B; Salvesen KA; Nakling J; Økland I; Borthen I; Rognerud Jensen OH; Kolås T; Løkvik B; Smedvig E
Acta Obstet Gynecol Scand; 2008; 87(9):916-23. PubMed ID: 18720044
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers.
Danielson BG; Salmonson T; Derendorf H; Geisser P
Arzneimittelforschung; 1996 Jun; 46(6):615-21. PubMed ID: 8767353
[TBL] [Abstract][Full Text] [Related]
32. Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose.
Conner TA; McQuade C; Olp J; Pai AB
Biometals; 2012 Oct; 25(5):961-9. PubMed ID: 22706571
[TBL] [Abstract][Full Text] [Related]
33. Intravenous iron sucrose: establishing a safe dose.
Chandler G; Harchowal J; Macdougall IC
Am J Kidney Dis; 2001 Nov; 38(5):988-91. PubMed ID: 11684551
[TBL] [Abstract][Full Text] [Related]
34. The effect of intravenous iron on oxidative stress in hemodialysis patients at various levels of vitamin C.
Eiselt J; Racek J; Opatrný K; Trefil L; Stehlík P
Blood Purif; 2006; 24(5-6):531-7. PubMed ID: 17077626
[TBL] [Abstract][Full Text] [Related]
35. Intravenous iron-gluconate during haemodialysis modifies plasma beta2-microglobulin properties and levels.
Michelis R; Sela S; Kristal B
Nephrol Dial Transplant; 2005 Sep; 20(9):1963-9. PubMed ID: 15956071
[TBL] [Abstract][Full Text] [Related]
36. Differences between original intravenous iron sucrose and iron sucrose similar preparations.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2009; 59(4):176-90. PubMed ID: 19517894
[TBL] [Abstract][Full Text] [Related]
37. Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients.
Atalay H; Solak Y; Acar K; Govec N; Turk S
Hemodial Int; 2011 Jul; 15(3):374-8. PubMed ID: 21564503
[TBL] [Abstract][Full Text] [Related]
38. Serum pro-hepcidin as an indicator of iron status in dialysis patients.
Tsuchihashi D; Abe T; Komaba H; Fujii H; Hamada Y; Nii-Kono T; Tanaka M; Fukagawa M
Ther Apher Dial; 2008 Jun; 12(3):226-31. PubMed ID: 18503700
[TBL] [Abstract][Full Text] [Related]
39. Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients.
Guz G; Glorieux GL; De Smet R; Waterloos MA; Vanholder RC; Dhondt AW
Nephrol Dial Transplant; 2006 Oct; 21(10):2834-40. PubMed ID: 16762960
[TBL] [Abstract][Full Text] [Related]
40. Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: a pilot study.
Anraku M; Kitamura K; Shintomo R; Takeuchi K; Ikeda H; Nagano J; Ko T; Mera K; Tomita K; Otagiri M
Clin Biochem; 2008 Oct; 41(14-15):1168-74. PubMed ID: 18692036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
